The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Official Title: A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma
Study ID: NCT05830500
Brief Summary: This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Gansu Cancer Hospital, Lanzhou, Gansu, China
Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University), Nanning, Guangxi, China
The First Affiliated Hospital of Hebei North University, Shijiazhuang, Hebei, China
Tianjin Cancer Hospital, Tianjin, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University, Nanjing, Jiangsu, China
Jiangsu North People's Hospital, Yangzhou, Jiangsu, China
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
Shanxi Provincial Tumor Hospital, Xi'an, Shanxi, China
Tianjin People's Hospital, Tianjin, Tianjin, China
The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China